Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $67.1 million.

  • Collegium Pharmaceutical's Operating Expenses rose 827.86% to $67.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $276.2 million, marking a year-over-year increase of 5324.95%. This contributed to the annual value of $207.4 million for FY2024, which is 3030.06% up from last year.
  • Collegium Pharmaceutical's Operating Expenses amounted to $67.1 million in Q3 2025, which was up 827.86% from $73.3 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Operating Expenses peaked at $75.6 million during Q1 2025, and registered a low of $32.0 million during Q3 2021.
  • For the 5-year period, Collegium Pharmaceutical's Operating Expenses averaged around $46.9 million, with its median value being $41.3 million (2022).
  • The largest annual percentage gain for Collegium Pharmaceutical's Operating Expenses in the last 5 years was 8267.56% (2024), contrasted with its biggest fall of 2045.1% (2024).
  • Over the past 5 years, Collegium Pharmaceutical's Operating Expenses (Quarter) stood at $32.8 million in 2021, then grew by 15.99% to $38.0 million in 2022, then decreased by 13.38% to $32.9 million in 2023, then skyrocketed by 82.68% to $60.2 million in 2024, then grew by 11.48% to $67.1 million in 2025.
  • Its Operating Expenses was $67.1 million in Q3 2025, compared to $73.3 million in Q2 2025 and $75.6 million in Q1 2025.